poisar

Stock

Aclarion, Inc. ACON

$2.43+1.04%

Overview

ACON market data

Price History

ACON price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$13.60
Diluted earnings per share over the trailing twelve months.
Beta
1.31
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-10,336.1%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1.95 – $12.03
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $6.9M · P/B 1.55 · P/S 88.83.

Company News

10 captured
Aclarion Says USPTO Issues Notice Of Allowance For U.S. Patent Application Titled Multi-Voxel Prescription For Lumbar Disc EvaluationBenzinga · Aug 12, 2026, 11:04 AM
Aclarion CEO Says In Letter To Shareholders Company Saw 141% Year-Over-Year Scan Volume Growth In First Half Of 2026; $16.3M Cash, No Debt With Runway Into Second Half Of 2027Benzinga · Jul 29, 2026, 11:04 AM
Aclarion Announces Texas Spine Care Center As New Clinical Site In Chronic Low bAck pain Randomized Independent Trial studY TrialBenzinga · Jul 7, 2026, 11:15 AM
Aclarion Receives Notice Of Allowance For A U.S. Patent On Its Multi-Voxel Prescription For Lumbar Disc EvaluationBenzinga · Jun 24, 2026, 8:05 PM
Aclarion Launches Market Access Program In Partnership With PRIA HealthcareBenzinga · Jun 9, 2026, 11:10 AM
Aclarion Board Reviews Echo Lake's Unsolicited Public Proposal And Unanimously Determined To Reject ItBenzinga · Jun 8, 2026, 11:20 AM
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence GenerationGlobenewswire Inc · Jun 3, 2026, 11:15 AM
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker StudyGlobenewswire Inc · Jun 1, 2026, 11:15 AM
Aclarion Announces That Its Nociscan Technology Was Used In A New Research Study Exploring The Biological Factors Associated With Back Pain In Patients With Modic Type 1 ChangesBenzinga · Jun 1, 2026, 10:04 AM
SentinelOne To Rally Nearly 40%? Here Are 10 Analyst Forecasts For FridayBenzinga · May 29, 2026, 12:33 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock